Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1066 participants.

Also called NCT01807221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,066 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01807221
  • EudraCT 2012-002627-15
Main results
  • A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease European heart journal, 2016-07-14 DOI, PubMed 27130705, PMC4946749 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01807221. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-17 (actual); primary completion 2014-11-11 (actual). Results posted on 2021-06-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
Acronym
ARTS-HF
Condition
Heart Failure
Intervention (Drug)
Finerenone (BAY94-8862)
Intervention (Drug)
Placebo
Intervention (Drug)
Inspra (eplerenone)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01807221
Content hash
e8ba0e3c23b3599a55d36784835a88272127ef6441c8f0866b719e3476f2afcd